Evidence map›Paper›PMID 41051902›Full record

ArticleJournal of the American Chemical Society2025

Covalent Probes Reveal Small-Molecule Binding Pockets in Structured RNA and Enable Bioactive Compound Design.

Sandra Kovachka, Jielei Wang, Amirhossein Taghavi, Yilin Jia, Taro Asaba, Karen C Wolff, Mason Martin, Xueyi Yang, Samantha M Meyer, Sabine Ottilie and 9 more

Abstract read
In one paragraph

Article in Journal of the American Chemical Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Nitro Reduction-Based RNA Control and Ultrafast Release.Angewandte Chemie (International ed. in English) · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Sandra KovachkaDepartment of Chemistry, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology (UF-Scripps), 130 Scripps Way, Jupiter, Florida 33458, United States.
Jielei WangDepartment of Chemistry, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology (UF-Scripps), 130 Scripps Way, Jupiter, Florida 33458, United States.
Amirhossein TaghaviDepartment of Chemistry, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology (UF-Scripps), 130 Scripps Way, Jupiter, Florida 33458, United States.
Yilin JiaDepartment of Chemistry, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology (UF-Scripps), 130 Scripps Way, Jupiter, Florida 33458, United States.
Taro AsabaDepartment of Chemistry, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology (UF-Scripps), 130 Scripps Way, Jupiter, Florida 33458, United States.
Karen C WolffCalibr-Skaggs Institute for Innovation Medicines at Scripps Research, La Jolla, California 92037, United States.
Mason MartinDepartment of Chemistry, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology (UF-Scripps), 130 Scripps Way, Jupiter, Florida 33458, United States.
Xueyi YangDepartment of Chemistry, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology (UF-Scripps), 130 Scripps Way, Jupiter, Florida 33458, United States.
Samantha M MeyerDepartment of Chemistry, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology (UF-Scripps), 130 Scripps Way, Jupiter, Florida 33458, United States.ORCID 0000-0003-3353-6939
Sabine OttilieCalibr-Skaggs Institute for Innovation Medicines at Scripps Research, La Jolla, California 92037, United States.ORCID 0000-0001-9797-2612
Mina HeacockCalibr-Skaggs Institute for Innovation Medicines at Scripps Research, La Jolla, California 92037, United States.
Zhong ChengCalibr-Skaggs Institute for Innovation Medicines at Scripps Research, La Jolla, California 92037, United States.
Case W McNamaraCalibr-Skaggs Institute for Innovation Medicines at Scripps Research, La Jolla, California 92037, United States.ORCID 0000-0002-5754-3407
Gurudutt DubeyCentro de Investigación Traslacional San Alberto Magno, Universidad Católica de Valencia, 46001 Valencia, Spain.
Arnab K ChatterjeeCalibr-Skaggs Institute for Innovation Medicines at Scripps Research, La Jolla, California 92037, United States.ORCID 0000-0001-5171-7982
Sumit ChandaCalibr-Skaggs Institute for Innovation Medicines at Scripps Research, La Jolla, California 92037, United States.
José GallegoCentro de Investigación Traslacional San Alberto Magno, Universidad Católica de Valencia, 46001 Valencia, Spain.ORCID 0000-0002-0627-6927
Jessica L Childs-DisneyDepartment of Chemistry, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology (UF-Scripps), 130 Scripps Way, Jupiter, Florida 33458, United States.
Matthew D DisneyDepartment of Chemistry, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology (UF-Scripps), 130 Scripps Way, Jupiter, Florida 33458, United States.ORCID 0000-0001-8486-1796

Funding

Targeting druggable coronavirus proteinsU19AI171443 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Juan C. de la Torre · 2022 to 2026
$101.4M
Translation Accelerator CoreU19AI171421 · NIAID · STANFORD UNIVERSITY · PI JEFFREY S GLENN · 2022 to 2026
$93.4M
NIAID NIH HHS U19 AI171421NIAID NIH HHS U19 AI171443
6 · The paper itself

Abstract

The SARS-CoV-2 frameshift stimulation element (FSE) is a critical RNA structure that is essential for viral replication and represents a promising target for antiviral intervention. Here, Chemical Cross-Linking and Isolation by Pull-down (Chem-CLIP) covalent target validation and binding site mapping was applied, to identify small-molecule binding pockets within the FSE and ultimately develop a ligandability map. These studies employed ∼ 190 Chem-CLIP fragments, including the fluoroquinolone merafloxacin, previously shown to interact with this element. Covalent mapping defined merafloxacin's binding pocket at a nucleotide-level resolution and revealed interactions that, along with structure-based design, efficient one-pot on-plate synthesis and competitive displacement assays, enabled the development of bioactive compounds with antiviral activity. Complementary chemical probing with dimethyl sulfate (DMS) in the presence of a bioactive ligand, coupled to Deconvolution of RNA Alternative Conformations (DRACO), revealed that compound binding increased the reactivity of specific nucleotides with DMS, indicative of changes in local RNA folding. These results highlight the importance of combining Chem-CLIP and DMS profiling to differentiate direct ligand binding from ligand-induced changes in RNA structure. In addition,

Indexed as

Antiviral AgentsDrug DesignRNA, ViralSARS-CoV-2Small Molecule LibrariesBinding SitesFluoroquinolonesHumansLigandsNucleic Acid ConformationAntiviral AgentsFluoroquinolonesLigandsRNA, ViralSmall Molecule Libraries

Identifiers

PMID41051902
PMCPMC12532193

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.